Gaussia luciferase as a reporter for quorum sensing in staphylococcus aureus by Blower, Isobel et al.
sensors
Article
Gaussia Luciferase as a Reporter for Quorum Sensing
in Staphylococcus aureus
Isobel Blower 1,† , Carmen Tong 1,2,†,‡, Xiaohui Sun 2,3, Ewan Murray 1, Jeni Luckett 1,
Weng Chan 4 , Paul Williams 1 and Philip Hill 1,2,*
1 School of Life Sciences, Biodiscovery Institute, University of Nottingham, University Park,
Nottingham NG7 2RD, UK; Isobel.Blower@nottingham.ac.uk (I.B.); C.Tong@sygnaturediscovery.com (C.T.);
Ewan.Murray@nottingham.ac.uk (E.M.); jeni.luckett@nottingham.ac.uk (J.L.);
paul.williams@nottingham.ac.uk (P.W.)
2 School of Biosciences, Sutton Bonington Campus, University of Nottingham, Loughborough LE12 5RD, UK;
sunxiaohui@hqu.edu.cn
3 College of Chemical Engineering, Huaqiao University, 668 Jimei Blvd, Xiamen 361021, China
4 School of Pharmacy, Biodiscovery Institute, University of Nottingham, University Park,
Nottingham NG7 2RD, UK; weng.chan@nottingham.ac.uk
* Correspondence: Phil.hill@nottingham.ac.uk
† These authors contributed equally to this work.
‡ Present address: Sygnature Discovery Limited, BioCity, Pennyfoot Street, Nottingham NG1 1GR, UK.
Received: 30 June 2020; Accepted: 30 July 2020; Published: 1 August 2020


Abstract: Gaussia luciferase (GLuc) is a secreted protein with significant potential for use as a reporter
of gene expression in bacterial pathogenicity studies. To date there are relatively few examples
of its use in bacteriology. In this study we show that GLuc can be functionally expressed in the
human pathogen Staphylococcus aureus and furthermore show that it can be used as a biosensor for
the agr quorum sensing (QS) system which employs autoinducing peptides to control virulence.
GLuc was linked to the P3 promoter of the S. aureus agr operon. Biosensor strains were validated
by evaluation of chemical agent-mediated activation and inhibition of agr. Use of GLuc enabled
quantitative assessment of agr activity. This demonstrates the utility of Gaussia luciferase for in vitro
monitoring of agr activation and inhibition.
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1. Introduction
Staphylococcus aureus has been identified by the World Health Organization as a high priority
pathogen [1]. It is one of the most common causes of bacterial infections in both hospitals and in the
community [2]. Infections caused by S. aureus are difficult to treat due to the ability of this bacterium to
acquire resistance to multiple antibiotics rapidly and to grow as a biofilm which limits the efficacy of
diverse antibiotics and biocides [3,4]. There is, therefore, an urgent need to develop antimicrobials
with novel targets which are effective against resistant strains. As well as traditional drugs, alternative
therapies are being investigated which are less likely to drive the development of resistance [5].
These include compounds which will target functions essential for infection such as colonization and
virulence factor production without affecting bacterial growth [6].
In S. aureus the accessory gene regulator (agr) quorum sensing system is a key regulator of
virulence factor expression [2,7]. Quorum sensing (QS) is a means of cell to cell communication in
bacterial populations. It coordinates cooperative behavior by enabling bacteria at high population
densities to respond to altered environments [8]. Bacteria communicate using secreted signal molecules
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called autoinducers. When the extracellular concentration of the autoinducer reaches a threshold level,
a signal transduction pathway is activated, leading to targeted gene activation or repression [7].
For the S. aureus agr system, as outlined in Figure 1, the quorum sensing signal molecule is
an autoinducing peptide (AIP) [9]. AIPs are produced by post-translational N- and C-terminal
processing of the AgrD pre-propeptide by AgrB and exported from the cell [7,10]. Once an AIP
reaches a threshold concentration outside the cell it binds to and activates AgrC in the cell membrane.
This autophosphorylates in response to AIP binding and in turn phosphorylates AgrA, the response
regulator. Activated AgrA binds to the P2 and P3 promoters, upregulating agrBCDA and RNAIII
expression [10–12]. RNAIII is the effector of the agr system, it encodes δ-haemolysin and also acts as a
regulatory RNA that controls expression of multiple virulence genes post-transcriptionally [7].
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directly inhibit Lux‐based bioluminescence, potentially leading to false positive hits [20]. Lux‐based 
Figure 1. Outline of the staphylococcal agr system and the P3 GLuc reporter. Critical control points
of the agr system, which are amenable to targeting by inhibitors, are indicated by blunt arrows.
CTZ represents coelenterazine and CTM coelenteramide. Adapted from [13].
There is in r asing evidence to sugg st that blocking S. aureus virulence gene expression attenuates
infection in certain experimental animal infection models [14,15]. This has been achieved through
mutation of agr or inhibition of agr via various natural and synthetic compounds. Inhibitors of agr
target different components within this quorum sensing system including those which target AgrB to
block AIP generation, competitive AIP inhibitors (also known as AgrC antagonists) which prevent
AgrC activation and inhibition of P2 and P3 activation by AgrA (Figure 1) [13]. Attenuating virulence
early in infection could allow the host immune system to respond and clear the pathogen, sparing
exposure to antibiotics [8]. Virulence inhibitors could also be used as adjuvants with existing antibiotics,
or with therapies which boost the host immune response [16,17].
Currently it is unclear when or where staphylococcal agr is expressed within the infection site and
whether agr inhibitors could be used against established infections or as prophylactics. In order to
investigate temporal agr expression and agr inhibition it is important to develop methods for real time
monitoring of agr activity which can be used in vivo [18]. This can be performed using bioluminescent
reporters linked to promoters of the agr system [19]. In previous studies, the Photorhabdus luminescens
lux operon linked to the agrP3 promoter has been used to measure temporal agr activation in infection
models and assess agr inhibitors in vivo [14,15]. agrP3 lux based systems have also been used for
high-throughput screening of agr inhibitors [12] though it has been reported that some compounds
such as Pseudomonas aeruginosa quorum sensing molecule 3-oxo-C12-HSL directly inhibit Lux-based
bioluminescence, potentially leading to false positive hits [20]. Lux-based systems also require oxygen
and so are potentially compromised in environmental niches where oxygen levels are low. In this
Sensors 2020, 20, 4305 3 of 12
study, a novel bioluminescent reporter linked to the P3 promoter of the agr system was validated for
use in S. aureus.
Luciferases are often used as biological reporters due to their high sensitivity, broad dynamic range
and operational simplicity. Luciferases have been used to monitor multiple cellular processes, such
as gene expression and protein interactions as well as tracking of bacterial and viral infection [21,22].
Traditionally, bacterial luciferases have been used as reporter genes in staphylococci, however this
system requires substrate and energy supply from the cells, at the point of live-cell assay. Novel
luciferases such as the Gaussia luciferase, which is small, secreted and ATP-independent, broaden the
potential applications and provide the ability to detect bioluminescence extracellularly and without
the need for extra energy from live cells at the point of the assay [23].
Gaussia luciferase (GLuc) is a naturally secreted enzyme from the marine copepod
Gaussia princeps [24]. GLuc is a 185 amino acid, 19.9 kDa luciferase which catalyses oxidative
decarboxylation of the substrate coelenterazine (CTZ) producing coelenteramide (CTM), emitting blue
light at 480 nm [25]. GLuc is nontoxic and is naturally secreted from the cell therefore is useful for
monitoring biological processes without the requirement for cellular energy to drive the luminescent
reaction [26]. GLuc is a useful reporter due to its small size and high light intensity, and hence
delivering assays with high sensitivity. GLuc is also stable at a wide range of pHs and is resistant
to heat shock and oxidative stress [27]. GLuc has been shown to be an effective biological reporter
in bacteria, such as Salmonella enterica and Mycobacterium smegmatis [26,28]. It is a highly sensitive
reporter for nondestructive quantification of in vivo biological processes ex vivo, as bioluminescence
can be detected from the blood or urine of in vivo models using a luminometer [29,30].
The aim of this work was to demonstrate the use of Gaussia luciferase as a reporter in S. aureus
and for monitoring activation of the agr quorum sensing system (see Figure 1). Reporter strains were
constructed with GLuc chromosomally encoded under the control of the agrP3 promoter in S. aureus
USA300 strain JE2 and an isogenic ∆agr mutant. These were validated by evaluation of activation
and inhibition of the agr system using the cognate AIP as agonist and synthetic (Ala5)AIP-1 as an
antagonist and by testing both nonpeptidic AgrC allosteric and AgrB inhibitors. The data obtained
show that GLuc can be used successfully for in vitro monitoring of agr activation and inhibition.
2. Materials and Methods
Staphylococcal strains were cultured in tryptone soy broth (TSB) (Oxoid) and E. coli in lysogeny
broth (LB) (Oxoid) with antibiotics added as required. All strains were grown at 37 ◦C and
overnight cultures were grown with aeration by shaking at 200 rpm. AIPs, N-(3-oxododecanoyl)
-L-homoserine lactone (3-oxo-C12-HSL, (S)-3-dodecanoyl-5-(2-hydroxyethyl) tetramic acid (C12-TMA)
and 3-dodecanoyltetronic acid (C12-TOA) were synthesized as described before. Ambuic acid was
purchased from Cayman Chemicals.
2.1. Construction of agrP3 Reporter S. aureus Strains
A transcriptional reporter fusion was constructed with Gaussia encoded chromosomally under
the control of the agrP3 promoter. All strains and primers used are listed in Tables 1 and 2, respectively.
To ensure GLuc would be secreted by S. aureus, the protein A (SpA) leader was engineered upstream
of a synthetic GLuc gene (kind gift of S. Wiles, University of Auckland, Auckland, New Zealand).
This replaced the sequence of the original native eukaryotic leader to direct the translated protein to
the S. aureus Sec secretory pathway. This fragment was assembled into pUNKdestR3R4 flanked by the
Pxyl/tet promoter and the rrnB1B2 transcriptional terminator to create plasmid pUNK1 pXyl/tet:SpA
leader:GLuc using Gateway cloning [31] and provided for constitutive expression of Gluc in S. aureus.
The GLuc gene was then amplified by PCR from this vector using primer pair CT16 and CT17 using
high fidelity Phusion DNA polymerase (Thermofisher). The agrP3 promoter was also amplified by
PCR from S. aureus 8325-4 genomic DNA using primer pair CT14 and CT15 and assembled upstream of
GLuc into pUNK1 using Hifi DNA assembly (NEB). This was used to transform electrocompetent E. coli
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DC10B. Plasmids were extracted using a miniprep kit (Qiagen) before confirmation by sequencing
(Source Bioscience).
Table 1. Bacterial strains used in this study.
Strain Description Reference
S. aureus 8325-4 Derivative of S. aureus NCTC 8325 [32]
S. aureus RN4220 attB2 Cloning intermediate [33]
S. aureus USA300 JE2 Plasmid-cured derivative of the CA-MRSA strainUSA300 LAC [34,35]
S. aureus RN4220 pXyl/tet: SpA
leader: GLuc Constitutively expressing SpA leader:GLuc This study
S. aureus RN4220
Pxyl/tet:::luxABCDE Constitutively bioluminescent strain [20]
S. aureus USA300 agrP3 Gluc USA300 with chromosomal integration of SpA leaderand GLuc under the control of agrP3 This study
S. aureus USA300 ∆agr P3 Gluc USA300 ∆agr with chromosomal integration of SpAleader and GLuc under the control of agrP3. This study
S. aureus ROJ143 ROJ143 carrying plasmid pSKermP2 agrC1 agrA [36]
S. aureus USA300 ∆agr P3 Gluc
pSKermP2 agrC1 agrA USA300 ∆agr P3 Gluc carrying pSKermP2 agrC1 agrA This study
E. coli DC10B Cloning intermediate dc [37]
Table 2. Primers used in this study. All primers were sourced from Sigma Aldrich (UK).
Primer Sequence Function Reference
CT12 (F) CTAGTAGGAGGAAAAACATATGATGACTTTACA
Amplification of SpA:GLuc This study
CT13 (R) ATTTGTCGACCTCAGGAGAGCGTTCACC
CT14 (F) AGTGAATTCCCGGGGATCCGACACGTCGACCCTCACTG
Amplification of agrP3 This study
CT15 (R) CTCCTACTAGCCATCACATCTCTGTGATCTAG
CT16 (F) GATGTGATGGCTAGTAGGAGGAAAAACATATGATG
Amplification of SpA:GLuc This study
CT17 (R) TCGATAAGCTTGGCTGCAGGATTTGTCGACCTCAGGAG
OU9R10 CATACTACATATCAACGAAATCAG Forward primer at RN4220 attB2integration site [33]
SCV4 ACCCAGTTTGTAATTCCAGGAG Reverse primer at 5
′ end of
pLL102 to RN4220 attB2 [33]
SCV8 GCACATAATTGCTCACAGCCA Forward primer at 3
′ end of
pLL102 to RN4220 attB2 [33]
OU9R7 ATGGGTGGTAAAACACAAATTTC Reverse primer at RN4220 attB2integration site [33]
Chromosomal integration of agrP3-GLuc into S. aureus was performed as outlined by Lei et al. [33]
using integration vector pLL102. Plasmids pUNK1 agrP3:SpA leader:GLuc and pLL102 were digested
with SalI and fragments ligated using T4 DNA ligase (NEB) and used to transform electrocompetent
E. coli DC10B to create plasmid pLL102 agrP3:SpA leader:GLuc. This plasmid was used to transform
electrocompetent S. aureus RN4220 attB2. Chromosomal integration was checked by colony PCR using
primer pairs OU9R10 and SCV4, and SCV8 and OU9R7 and the correct strain named S. aureus RN4220
attB2 agrP3 SpA leader GLuc. This strain was used as a donor for phage transduction into S. aureus
USA300 strain JE2 using phage phi11 (Φ11). Further phage transduction was performed with a ∆agr
Φ11 phage lysate. This resulted in the construction of reporter strains USA300 agrP3-GLuc and USA300
∆agr P3 GLuc.
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2.2. Measuring agrP3 Promoter Activity Using GAUSSIA Luciferase Bioluminescence
When testing bioluminescence output from GLuc over time, a single colony of the test strain
was used to inoculate 50 mL of TSB, which was incubated at 37 ◦C, 200 rpm. An OD600 reading of a
1 mL sample was taken every hour for 12 h. The supernatant fraction was separated from the cells by
centrifugation twice at 13,000× g for 2 min. Samples were stored at −20 ◦C prior to analysis. Freeze
thawing has been shown to have no effect on the stability of Gaussia luciferase [38]. When testing the
effect of AIP-1 and ambuic acid, a single colony was grown in 5 mL of TSB broth for 16 h with test
compounds added at the desired concentrations at the start of incubation. When testing the effect of
Ala5(AIP-1) and 3-oxo-C12-HSL analogues these compounds were added to broth with a single colony
as before and incubated for 6 h. Cultures were incubated at 37 ◦C at 200 rpm and samples taken as
described previously.
Samples were thawed at room temperature and 100 µL loaded into a black, flat clear-bottomed 96
well plate (Greiner). Bioluminescence was recorded as Relative Light Units (RLU) using a 96 well-plate
reader and injector (Infinite F200 Tecan): 50 µL of 20 µM coelenterazine (CTZ) substrate was injected at
200 µL/s and bioluminescence read with an integration time of 100 ms after a wait time of 1 s. A portion
of 20 µM CTZ was used as this was shown to saturate the enzyme. CTZ was injected into each well and
bioluminescence read in turn, 3 technical repeats were recorded for each sample. Statistical analysis
was performed using an unpaired t-test with Welch’s correction.
3. Results
3.1. Induction of agr with Respect to Growth Phase
In S. aureus, agr-dependent quorum sensing is activated at high cell population densities when
the autoinducing AIP reaches a threshold level. This has been reported to occur in vitro in the late
exponential/early stationary phase of growth [11]. When the AIP reaches the threshold concentration
the agrP3 promoter is activated, therefore GLuc expression will be induced via agrP3. In order to
determine whether the production of GLuc bioluminescence occurs as a function of the growth phase
consistent with agr induction, bioluminescence and OD600 were quantified over 12 h using S. aureus
USA300 agrP3-GLuc.
A single colony was inoculated into 50 mL TSB broth with 0.01% v/v DMSO added as a solvent
control. Growth did not appear to be attenuated. As shown in Figure 2a, light output was observed after
6–7 h of growth. From 5–7 h, the level of bioluminescence increased substantially, from ~4.83 × 105 to
8.74× 106 RLU/OD600 (Relative Light Units/Optical Density at 600 nm). The increase in bioluminescence
reached a plateau after 10 h at ~2.7 × 107 RLU/OD600 which is consistent with agr expression.
3.2. Activation of USA300 ∆agr P3-GLuc pSKermP2 agrAC with Synthetic AIP-1
To confirm the AIP-dependent expression of the agrP3-Gluc construct we set out to demonstrate
that the reporter can be activated with synthetic, exogenous AIP-1. The agrA and agrC genes which
constitute the agr two-component signal transduction system, were introduced into USA300 ∆agr
P3-GLuc on plasmid pSKermP2 agrAC [36]. Genetic complementation with agrA and agrC would
enable the strain to respond to exogenous AIP-1 by upregulation of the agrP3-GLuc promoter due to
signal transduction from AgrC and AgrA [36]. Due to the lack of AgrB and AgrD the strain could not
itself synthesize AIP-1.
The response of this strain to synthetic AIP-1 was demonstrated by the addition of 100 nM AIP-1
to an overnight culture. As a control, 0.01% v/v DMSO, the solvent used for AIP-1 was tested, as well
as USA300 ∆agr P3-GLuc with addition of 100 nM AIP-1.































































Figure 2. Bioluminescence from S. aureus strain USA300 agrP3-GLuc over time. (a) Bioluminescence
output. (b) Bacterial growth (OD600). Data are representative of three technical repeats and three
biological repeats for each sample with error bars displaying standard deviations.
As sh wn in Figure 3 after addition of AIP-1 to USA300 ∆agr P3-GLuc the level of bioluminescence
was ~6.78 × 106 RLU/OD600. This demonstrates that AIP-1 does not activate quorum sensing in
the ∆agr strain. When complemented with agrA and agrC, the 0.01% v/v DMSO control produced
bioluminescence of ~1.4 × 107 RLU/OD600, indicating the levels of background luminescence when the
AgrA transcription ctivator was present. On exogenous provision of 100 nM AIP-1 this increased to

















increased  to ~4.19 × 107 RLU/OD600. This was a significant  increase showing  the strain  responded 
productively to exogenous AIP‐1. 
 
Figure  3.  Impact  of  the  addition  of  exogenous AIP‐1  on  bioluminescence  produced  by  S.  aureus 




To demonstrate  that GLuc  expression  is under  the  control  of  the  agrP3 promoter,  S.  aureus 
USA300  agrP3‐GLuc was  treated with  (Ala5)AIP‐1, a  competitive  inhibitor of  the  agr  system  [39]. 
Bioluminescence was recorded after incubation for 6 h. As shown in Figure 4, after 6 h there was a 
significant decrease in bioluminescence observed when treated with 100 nM (Ala5)AIP‐1 (~6.4 × 105 
RLU)  compared  with  the  1%  v/v  DMSO  control  (1.13  ×  106  RLU).  This  demonstrates  that 
bioluminescence from this strain can be inhibited with addition of a competitive antagonist of the agr 
system. 
Figure 3. Impact of the addition of exogenous AIP-1 on bioluminescence produced by S. aureus USA300
∆agr P3-Gluc pSKermP2 agrAC. ∆agr represents USA300 ∆agr P3-GLuc and ∆agr + AC represents
USA300 ∆agr P3-Gluc pSKermP2 agrAC. The data represent three technical repeats and three biological
repeats for each sample and error bars displaying standard deviation. * p < 0.01.
3.3. Inhibition of S. aureus USA300 agrP3 by an AgrC Antagonist (Ala5)AIP-1
To demonstrate that GLuc expression is under the control of the agrP3 promoter, S. aureus
USA300 agrP3-GLuc was treated with (Ala5)AIP-1, a competitive inhibitor of the agr system [39].
Bioluminescence was recorded after incubation for 6 h. As shown in Figure 4, after 6 h there
was a significant decrease in bioluminescence observed when treated with 100 nM (Ala5)AIP-1
(~6.4 × 105 RLU) compared with the 1% v/v DMSO control (1.13 × 106 RLU). This dem nstrates that
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has  inhibitory  effects  on  the  S.  aureus  agr  quorum  sensing  system  [40]. Murray  et  al.  screened 
Figure 4. Impact of Ala5(AIP-1) on bioluminescence output from S. aureus USA300 agrP3-GLuc. The 1%
v/v DMSO represents USA300 agrP3 GLuc with 1% DMSO, ∆agr represents USA300 ∆agr P3-GLuc
and 100 nM Ala-5 represents USA300 agrP3 GLuc with addition of 100 nM (Ala5)AIP-1. The data
shown are the means with error bars displaying standard deviation of triplicate technical repeats and is
representative of biological triplicate repeats. * p < 0.01.
3.4. Evaluation of an AgrB Inhibitor with SA300 agrP3-GLuc
Inhibitors of other targets in the agr system have been identified, such as ambuic acid which
blocks AIP biosynthesis by targeting AgrB [15]. This was tested against USA300 agrP3-GLuc. Addition
of 40 µM ambuic acid significantly reduced bioluminescence compared with the control to 2.52 × 107
RLU/OD600 (Figure 5). This was almost 4-fold lower than the control although bioluminescence was
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The m lecule 3‐Ox ‐C12‐H L is a Pseudomonas aerugi osa quoru  sensing sign l molecule which 
has  inhibitory  effects  on  the  S.  aureus  agr  quorum  sensing  system  [40]. Murray  et  al.  screened 
Figure 5. Impact of the AIP biosynthesis inhibitor ambuic acid (40 µM) on bioluminesce ce output
from S. aureus USA300 agrP3-GLuc. ‘No compound’ represents USA300 agrP3 GLuc without inhibitor,
∆agr represents USA300 ∆agr P3-GLuc without inhibitor and ambuic acid represents USA300 agrP3
GLuc with the addition of 40 µM ambuic acid. The graph displays the mean of three technical and
three biological repeats with error bars displaying standard deviation. * p < 0.01.
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3.5. 3-Oxo-C12-HSL Has Differential Effects on GLuc and Lux Bioluminescence
The molecule 3-Oxo-C12-HSL is a Pseudomonas aeruginosa quorum sensing signal molecule which
has inhibitory effects on the S. aureus agr quorum sensing system [40]. Murray et al. screened analogues
of 3-oxo-C12-HSL and identified C12-TMA and C12-tetronic acid (C12-TOA) as the most potent inhibitors.
They used a blaZ based agrP3 reporter as 3-oxo-C12-HSL affected lux-based bioluminescence making
conventional lux-based agrP3 reporter systems unsuitable [40].
To determine whether a GLuc-based reporter could be used to screen for quorum sensing inhibitory
activity with compounds that inhibited Lux-based bioluminescence, 3-oxo-C12-HSL, C12-TMA and
C12-TOA were mixed with Gaussia luciferase in the supernatant of Gluc-expressing S. aureus to
investigate whether they directly influenced the GLuc biochemical reaction. They were also tested
on cultures of constitutively bioluminescent S. aureus expressing lux to compare the effect on lux-
based bioluminescence.
As shown in Figure 6, neither 3-oxo-C12-HSL nor C12-TMA significantly affected GLuc
bioluminescence compared with a 1% v/v DMSO solvent control. However, when these two compounds
were incubated with Lux + S. aureus at 5 µM, light output was significantly reduced. This confirmed
that lux-based bioluminescence was directly inhibited by these compounds. C12-TOA was not shown
to significantly decrease either GLuc or lux-based bioluminescence at both concentrations tested.
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Figure 6. Comparison of the effect of 3-oxo-C12-HSL, C12-TMA and C12-TOA on S. aureus constitutively
expressing bioluminescence based on (a) GLuc or (b) Lux. The data shown are the means with error
bars displaying standard deviation of triplicate technical repeats and are representative of biological
triplicate repeats. ** p < 0.05.
3.6. Evaluation of USA300 agrP3 GLuc as a Screen for agr Inhibitors Related to 3-oxo-C12-HSL
To evaluate whether S. aureus USA300 agrP3 GLuc could be used to screen analogues of
3-oxo-C12-HSL, this strain was c ltured in the prese ce or abs nce of a range of concentrations
of 3-oxo-C12-HSL, C12-TMA and C12-TOA and bioluminescence read after 6 h. As shown in Figure 7,
addition of 5 µM or 10 µM of 3-oxo-C12-HSL significantly reduced bioluminescence compared to the 1%
DMSO control. The addition of C12-TMA and C12-TOA also reduced bioluminescence which confirmed
findings of agr inhibition by these compounds reported by Murray et al. (2014). This demonstrates
that S. aureus USA300 agrP3 GLuc can be used to screen inhibitors of agr-dependent quorum sensing,
where screening by Lux is precluded due to direct inhibition of Lux bioluminescence.
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Figure 7. The effect of 3-oxo-C12-HSL, C12-TMA and C12-TOA on agrP3-GLuc expression in USA300
agrP3 GLuc. For 3-oxo-C12-HSL, low luminescence values of 1.9 × 104 RLU/OD600 (5 µM) and
2.45 × 104 RLU/OD600 (10 µM) were recorded. The data show the means with error bars displaying
standard deviation of triplicate technical repeats and are representative of biological triplicate repeats.
*** p < 0.0001.
. isc ssi
ti i tic resistance in many bacterial p thogens including S. aureus is increasing and antibiotics
of last resort are increasingly used to treat these infections, which in turn is leading to the emergence of
resistance t these high-value antibiotics. There is an urgent need for novel therapeutics which do not
succumb to conventional mecha isms of antibiotic resistance. One method is through attenuati n of
bacterial virulence. In S. aureus, pathogenicity is largely controlled by the agr quorum sensing syste ,
therefore this is a pot ntial target for antivirulence drugs [13,41]. It is therefore important to develop
simple methods for monitoring of agr activity in order to facilitate screening for inhibitors a d ain
i formation about agr activation in infection models i vivo. In this study we have demonstrat d that
Gaussia luciferase can be used as a reporter for agr dependent qu rum sensi g i S. aure s. The ability
of GLuc to report agr activation in vitr was demonstrated by comp ring bi lumin scence over time
with OD600. This showed that bioluminescence increased in the late log phase of growth when agr is
activated [11]. This confirmed that the reporter functioned s anticipated and is likely to be useful
for monitoring t mporal agr activation both in vitro and pote tially i ivo in ex erimental animal
i f ction models.
tr t t t ti ti i r t tr l f t r t , t r t
t ti I - fir t l t . ti ti f t r t i itr i il t . re s tr i
iti f t tic I - iffi lt t f t l t f
t r t . For exa ple, od represses agr activation during exponential gro t in rich edia,
ti ti ti f l ti f t i t [ ]. r f r , i t l t t
f t t t I - , i t e t o-c t si l
t ti system wer introduced into USA300 ∆agr P3-GLuc on plasmid pSKermP2. This plasmid
encodes agrC and agrA under the control of the P2 promoter of the agr system [36]. Complementation
of agrA and agrC enabled the ∆agr strain to respond to exogenous AIP-1. This was shown by the
increased light output on provision of AIP-1 compared with the DMSO control.
It as de onstrated that for S 300 agrP3- Luc the expression of Gaussia luciferase as
dependent on activation of the agr S syste . This as further validated by addition of a co petitive
antagonist of the agr syste . ddition of ( la5) IP-1 reduced biolu inescence. This confir ed that
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inhibition of the agr system also inhibited GLuc activation, which was consistent with the control
of light output through activation of QS. Similar results were obtained with C12-TMA and C12-TOA
which are noncompetitive, negative allosteric modulators of AgrC [40].
This work also demonstrates the potential of the GLuc reporter in identifying inhibitors of other
agr system components. Ambuic acid, an AgrB inhibitor, was tested against USA300 agrP3-GLuc.
Ambuic acid has been tested previously in in vivo models with an agrP3-lux reporter where real time
reduction of agr activity was seen [15]. This shows that GLuc can be used as a reporter to screen for agr
inhibitors and evaluate their potential as prophylactic and therapeutic agents.
Previously, bacterial lux-based reporter systems have been used to study agr quorum sensing
however it has been demonstrated that some agr inhibitors can interfere with the luciferase activity
giving false results. Here it was demonstrated that 3-oxo-C12 HSL interfered with the lux signal
however did not interfere with GLuc bioluminescence. It was shown that QS inhibitors which have
an effect on lux-based bioluminescence could be reliably assayed using GLuc, demonstrating that it
was a useful alternative output for bacterial reporter systems. Additionally, the output from lux-based
reporters may be affected by metabolic effects decreasing the availability of bioluminescence substrates
such as FMNH2 at the point of assay, therefore any reduction in bioluminescence could be due to
metabolic factors rather than a reduction of agr activity [43]. GLuc does not require cellular cofactors
during assay therefore directly provides information about agr activation, avoiding the reduction in
specificity associated with the loss of metabolites. This work demonstrates that agrP3 GLuc reporters
can be used as a useful alternative or adjunct to screens for inhibitors of the agr system in vitro.
Together these data show that the agrP3-GLuc reporter can be activated by exogenous cognate AIP-1
and inhibited by antagonists of the agr system similar to agrP3-lux and agrP3-blaZ reporters [36,39,44].
This highlights the use of the Gaussia luciferase as a novel reporter of agr activity in S. aureus in vitro
and for potential screening for activators and inhibitors of the agr system.
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